arrow
M

Marcello Guagliò

irccs istituto nazionale tumori milano
H指数:28
被引数:4,093

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ASO Visual Abstract: Mesenteric Peritonectomy as the Seventh Peritonectomy Technique in Cytoreductive Surgery for Peritoneal Surface Malignancies: a Propensity Score-Matched Analysis

ASO可视化摘要:在细胞减灭术治疗腹膜表面恶性肿瘤中,肠系膜腹膜切除术作为第七种腹膜切除术技术:一项倾向性评分匹配分析

2026-09-300
PRE
Comparative oncological efficacy of chemotherapy, cytoreductive surgery with or without HIPEC in recurrent ovarian cancer: A network meta-analysis

化疗、减瘤术(含或不含HIPEC)治疗复发性卵巢癌的肿瘤学疗效比较:一项网络Meta分析

EJSO
IF2.9
2026-09-110
PRE
Tailoring HIPEC with Patient-Derived Organoids in Colorectal Peritoneal Metastases: Results from the First Stage of the Prospective Phase II OrganoHIPEC Clinical Trial (Clinicaltrials.gov NCT06057298)

利用患者源性类器官定制腹腔热灌注化疗(HIPEC)治疗结直肠癌腹膜转移:前瞻性II期OrganoHIPEC临床试验第一阶段的成果(Clinicaltrials.gov NCT06057298)

Cancers
IF4.4
2026-08-280
OA
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden
2024-11-040
OAAI
Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside (vol 43, 132, 2024)
2024-06-110
OAAI
Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside
2024-05-026
OAAI
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin
2023-12-013
PRE
A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei

腹膜假性粘液瘤中A2AR的表达和免疫抑制环境与KRAS和GNAS突变无关

2023-07-204
OAAI